COVID-19-associated coagulopathy.
Anticoagulants
/ therapeutic use
Betacoronavirus
/ genetics
Blood Coagulation Disorders
/ etiology
COVID-19
Coronavirus Infections
/ complications
Humans
Inflammation
/ complications
Pandemics
Pneumonia, Viral
/ complications
SARS-CoV-2
Severity of Illness Index
Thromboembolism
/ drug therapy
Thrombosis
/ epidemiology
COVID-19
SARS-CoV-2
anticoagulant therapy
prophylaxis
thromboembolism
thrombosis
Journal
Diagnosis (Berlin, Germany)
ISSN: 2194-802X
Titre abrégé: Diagnosis (Berl)
Pays: Germany
ID NLM: 101654734
Informations de publication
Date de publication:
18 Nov 2020
18 Nov 2020
Historique:
received:
05
06
2020
accepted:
03
07
2020
pubmed:
20
7
2020
medline:
27
11
2020
entrez:
20
7
2020
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been recently recognized as a systemic disorder inducing a prothrombotic state. The molecular mechanisms underlying the hypercoagulable state seen in patients with COVID-19 is still incompletely understood, although it presumably involves the close link between inflammatory and hemostatic systems. The laboratory coagulation monitoring of severely ill COVID-19 patients is mandatory to identify those patients at increased thrombotic risk and to modulate thromboprophylaxis accordingly. In this review, we summarize the current understanding on the pathogenesis, epidemiology, clinical and laboratory features and management of coagulopathy associated with COVID-19.
Identifiants
pubmed: 32683333
doi: 10.1515/dx-2020-0078
pii: dx-2020-0078
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
357-363Références
Zhai, P, Ding, Y, Wu, X, Long, J, Zhong, Y, Li, Y. The epidemiology, diagnosis, and treatment of COVID-19. Int J Antimicrob Agents 2020;55:105955. https://doi.org/10.1016/j.ijantimicag.2020.105955.
Zhou, F, Yu, T, Du, R, Fan, G, Liu, Y, Liu, Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62. https://doi.org/10.1016/s0140-6736(20)30566-3.
Peeri, NC, Shrestha, N, Rahman, MS, Zaki, R, Tan, Z, Bibi, S, et al. The SARS, MERS, and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol 2020 Feb 22. https://doi.org/10.1093/ije/dyaa033 [Epub ahead of print].
Xie, M, Chen, Q. Insight into 2019 novel coronavirus – an updated interim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis 2020 Apr 1. https://doi.org/10.1016/j.ijid.2020.03.071 [Epub ahead of print].
Holshue, ML, DeBolt, C, Lindquist, S, Lofy, KH, Wiesman, J, Bruce, H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020;382:929–36. https://doi.org/10.1056/nejmoa2001191.
World Health Organization. Coronavirus disease (COVID-19) outbreak. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [Accessed 24 Apr 2020].
Franchini, M, Farrugia, A, Velati, C, Zanetti, A, Romanò, L, Grazzini, G, et al. The impact of the SARS-CoV-2 outbreak on the safety and availability of blood transfusions in Italy. Vox Sang 2020 April 2. https://doi.org/10.1111/vox.12928 [Epub ahead of print].
Zhang, L, Liu, Y. Potential interventions for novel coronavirus in China: a systematic review. J Med Virol 2020;92:479–90. https://doi.org/10.1002/jmv.25707.
Rome, BN, Avorn, J. Drug evaluation during the COVID-19 pandemic. N Engl J Med 2020 Apr 14. https://doi.org/10.1056/nejmp2009457 [Epub ahead of print].
Wong, HK, Lee, CK. Pivotal role of convalescent plasma in managing emerging infectious diseases. Vox Sang 2020 Apr 2. https://doi.org/10.1111/vox.12927 [Epub ahead of print].
Chen, L, Xiong, J, Bao, L, Shi, Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020;20:398–400. https://doi.org/10.1016/s1473-3099(20)30141-9.
Roback, JD, Guarner, J. Convalescent plasma to treat COVID-19: possibilities and challenges. J Am Med Assoc 2020 Mar 27. https://doi.org/10.1001/jama.2020.4940 [Epub ahead of print].
Casadevall, A, Pirofski, LA. The convalescent sera option for containing COVID-19. J Clin Invest 2020;130:1545–8. https://doi.org/10.1172/jci138003.
Shen, C, Wang, Z, Zhao, F, Yang, Y, Li, J, Yuan, J, et al. Treatment of five critically ill patients with COVID-19 with convalescent plasma. J Am Med Assoc 2020;323:1582–9. https://doi.org/10.1001/jama.2020.4783.
Duan, K, Liu, B, Li, C, Zhang, H, Yu, T, Qu, J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020;117:9490–6. https://doi.org/10.1073/pnas.2004168117.
Li, L, Zhang, W, Hu, Y, Tong, X, Zheng, S, Yang, J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. J Am Med Assoc 2020 Jun 3. https://doi.org/10.1001/jama.2020.10044 [Epub ahead of print].
Tal, S, Spectre, G, Kornowski, R, Perl, L. Venous thromboembolism complicated with COVID-19: what do we know so far? Acta Haematol 2020;143:417–24. https://doi.org/10.1159/000508233.
Giannis, D, Ziogas, IA, Gianni, P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV, and lessons from the past. J Clin Virol 2020;127:104362. https://doi.org/10.1016/j.jcv.2020.104362.
Connors, JM, Levy, JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020 Apr 27. https://doi.org/10.1182/blood.2020006000 [Epub ahead of print].
Leisman, DE, Deutschman, CS, Legrand, M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med 2020 Apr 28. https://doi.org/10.1007/s00134-020-06059-6 [Epub ahead of print].
Lee, SG, Fralick, M, Sholzberg, M. Coagulopathy associated with COVID-19. Can Med Assoc J 2020 May 25. https://doi.org/10.1503/cmaj.200685 [Epub ahead of print].
Levi, M, Thachil, J, Iba, T, Levy, JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020;7:e438–40. https://doi.org/10.1016/s2352-3026(20)30145-9.
Thachil, J, Tang, N, Gando, S, Falanga, A, Cattaneo, M, Levi, M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020;18:1023–6. https://doi.org/10.1111/jth.14810.
Terpos, E, Ntanasis-Stathopoulos, I, Elalamy, I, Kastritis, E, Sergentanis, TN, Politou, M, et al. Hematological findings and complications of COVID-19. Am J Hematol 2020 Apr 13. https://doi.org/10.1002/ajh.25829 [Epub ahead of print].
Bikdeli, B, Madhavan, MV, Jimenez, D, Chuich, T, Dreyfus, I, Driggin, E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020;75:2950–73. https://doi.org/10.1016/j.jacc.2020.04.031.
Liu, Z, Xiao, X, Wei, X, Li, J, Yang, J, Tan, H, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol 2020;92:595–601. https://doi.org/10.1002/jmv.25726.
Becker, RC. COVID-19 update: COVID-19-associated coagulopathy. J Thromb Thrombolysis 2020 May 15. https://doi.org/10.1007/s11239-020-02134-3 [Epub ahead of print].
Gralinski, LE, Sheahan, TP, Morrison, TE, Menachery, VD, Jensen, K, Leist, SR, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio 2018;9:1–15. https://doi.org/10.1128/mbio.01753-18.
Henry, BM, de Oliveira, MHS, Benoit, S, Plebani, M, Lippi, G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020;58:1021–8.
Debuc, B, Smadja, DM. Is COVID-19 a New hematologic disease? Stem Cell Rev Rep 2020 May 12. https://doi.org/10.1007/s12015-020-09987-4 [Epub ahead of print].
Guan, WJ, Ni, ZY, Hu, Y, Liang, WH, Ou, CQ, He, JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20. https://doi.org/10.1056/nejmoa2002032.
Tang, N, Li, D, Wang, X, Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844–47. https://doi.org/10.1111/jth.14768.
Huang, C, Wang, Y, Li, X, Ren, L, Zhao, J, Hu, Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. https://doi.org/10.1016/s0140-6736(20)30183-5.
Petrilli, CM, Jones, SA, Yang, J, Rajagopalan, H, O’Donnel, L, Chernyak, Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020;369:m1966. https://doi.org/10.1136/bmj.m1966.
Lippi, G, Plebani, M, Henry, BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta 2020. https://doi.org/10.1016/j.cca.2020.03.022 [Epub ahead of print].
Yang, X, Yang, Q, Wang, Y, Wu, Y, Xu, J, Yu, Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost 2020;18:1469–72. https://doi.org/10.1111/jth.14848.
Fogarty, H, Townsend, L, Ni Cheallaigh, C, Bergin, C, Martin-Loeches, I, Browne, P, et al. COVID19 coagulopathy in Caucasian patients. Br J Haematol 2020. https://doi.org/10.1111/bjh.16749 [Epub ahead of print].
Spiezia, L, Boscolo, A, Poletto, F, Cerruti, L, Tiberio, I, Campello, E, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acure respiratory failure. Thromb Haemost 2020;120:998–1000. https://doi.org/10.1055/s-0040-1710018.
Ranucci, M, Ballotta, A, Di Dedda, U, Bayshnikova, E, Dei Poli, M, Resta, M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020 Apr 17. https://doi.org/10.1111/jth.14854 [Epub ahead of print].
Wright, FL, Vogler, TO, Moore, EE, Moore, HB, Wohlauer, MV, Urban, S, et al. Fibrinolysis shutdown correlates to thromboembolic events in severe COVID-19 infection. J Am Coll Surg 2020 May 15. https://doi.org/10.1016/j.jamcollsurg.2020.05.007 [Epub ahead of print].
Wada, H, Thachil, J, Di Nisio, M, Kurosawa, S, Gando, S, Toh, CH. Scientific and standardization committee on DIC of the international society on thrombosis and haemostasis. Harmonized guidance for disseminated intravascular coagulation from the international society on thrombosis and haemostasis and the current status of anticoagulant therapy in Japan: a rebuttal. J Thromb Haemost 2013;11:2078–9. https://doi.org/10.1111/jth.12366.
Zhai, Z, Li, C, Chen, Y, Gerotziafas, G, Zhang, Z, Wan, J, et al. Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines. Thromb Haemost 2020;120:937–48. https://doi.org/10.1055/s-0040-1710019.
Lodigiani, C, Iapichino, G, Carenzo, L, Cecconi, M, Ferrazzi, P, Sebastian, T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 2020;191:9–14. https://doi.org/10.1016/j.thromres.2020.04.024.
Klok, FA, Kruip, MJHA, van der Meer, NJM, Arbous, MS, Gommers, DAMPJ, Kant, KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–7. https://doi.org/10.1016/j.thromres.2020.04.013.
Helms, J, CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis), Tacquard, C, Severac, F, Leonard-Lorant, I, Ohana, M, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study, Intensive Care Med 2020. https://doi.org/10.1007/s00134-020-06062-x [Epub ahead of print].
Poissy, J, Goutay, J, Caplan, M, Parmentier, E, Duburcq, T, Lassalle, F, et al. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation 2020 Apr 24. https://doi.org/10.1161/circulationaha.120.047430 [Epub ahead of print].
Tian, S, Hu, W, Niu, L, Liu, H, Xu, H, Xiao, SY. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol 2020;15:700–4. https://doi.org/10.1016/j.jtho.2020.02.010.
Cui, S, Chen, S, Li, X, Liu, S, Wang, F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020. https://doi.org/10.1111/jth.14830 [Epub ahead of print].
Dolhnikoff, M, Duarte-Neto, AN, de Almeida Monteiro, RA, da Silva, LFF, de Oliveira, EP, Saldiva, PHN, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost 2020;18:1517–9. https://doi.org/10.1111/jth.14844.
Llitjos, J-F, Leclerc, M, Chocois, C, Monsallier, JM, Ramakers, M, Auvray, M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020. https://doi.org/10.1111/jth.14869 [Epub ahead of print].
Tang, N, Bai, H, Chen, X, Gong, J, Li, D, Sun, Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18:1094–9. https://doi.org/10.1111/jth.14817.
Yin, S, Huang, M, Li, D, Tang, N. Difference of coagulation features between severe pneumonia induced by SARSCoV2 and non-SARS-CoV2. J Thromb Thrombolysis 2020 Apr 3. https://doi.org/10.1007/s11239-020-02105-8 [Epub ahead of print].
Poterucha, TJ, Libby, P, Goldhaber, SZ. More than an anticoagulant: do heparins have direct anti-inflammatory effects? Thromb Haemost 2017;117:437–44. https://doi.org/10.1160/th16-08-0620.
WHO. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected.
Casini, A, Alberio, L, Angelillo-Scherrer, A, Fontana, P, Gerber, B, Graf, L, et al. Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19 – a Swiss consensus statement by the Working Party Hemostasis. Swiss Med Wkly 2020;150:w20247. https://doi.org/10.4414/smw.2020.20247.
Iba, T, Levy, JH, Levi, M, Connors, JM, Thachil, J. Coagulopathy of coronavirus disease 2019. Crit Care Med 2020 May 27. https://doi.org/10.1097/ccm.0000000000004458 [Epub ahead of print].
Khan, IH, Savarimuthu, S, Tsun Leung, MS, Harky, A. The need to manage the risk of thromboembolism in COVID-19 patients. J Vasc Surg 2020. https://doi.org/10.1016/j.jvs.2020.05.015 [Epub ahead of print].
Coppola, A, Lombardi, M, Tassoni, MI, Carolla, G, Tala, M, Morandini, R, et al. COVID-19, thromboembolic risk and thromboprophylaxis: learning lessons from the bedside, awaiting evidence. Blood Transfus 2020;18:226–9.
Marietta, M, Ageno, W, Artoni, A, De Candia, E, Gresele, P, Marchetti, M, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus 2020;18:167–9. https://doi.org/10.2450/2020.0083-20.